Alpha-gal syndrome

Summary

Alpha-gal syndrome (MONDO:0100001) is a disease and 6 clinical trials. A subtype of allergic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	alpha-gal syndrome
Mondo ID	MONDO:0100001
DOID	DOID:0070659
UMLS	C5442181
MedGen	1778444
Is cancer (heuristic)	no

Also known as: AGS · allergic galactose-alpha-1,3-galactose disease · alpha-gal allergy · red meat allergy · tick bite meat allergy

Disease family

This is a subtype of allergic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › hypersensitivity reaction disease › allergic disease › alpha-gal syndrome

Related subtypes (11): allergic respiratory disease, drug allergy, gastrointestinal allergy, latex allergy, atopic eczema, atopic IgE-mediated allergic disorder, eye allergy, vulvovaginitis, allergic seminal, allergic otitis media, venom allergy, food allergy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07611435	PHASE2	NOT_YET_RECRUITING	Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG
NCT03047369	Not specified	RECRUITING	The Myelin Disorders Biorepository Project
NCT05635266	Not specified	RECRUITING	Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT06268717	Not specified	RECRUITING	GI Alpha-Gal Study
NCT07177729	Not specified	RECRUITING	The α-gal Syndrome - Investigating Immune Reactions to Tick Bites
NCT02699190	Not specified	COMPLETED	LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies